Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended...
Biotech
Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
China-based Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi‑annual financial results for...
Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement...
Junshi Biosciences Reports 49% Revenue Growth in H1 2025
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released its interim financials for the...
Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. (HKG: 2592) announced a positive profit alert for the...
Minova Rongzhi Funding Surge: Series B Backed by IDG Capital
Nanjing‑based Minova Pharmaceuticals Co., Ltd. closed a Series B financing round worth hundreds of millions of...
Henlius, Serplulimab and Abbott Drive Robust 2025 Financials
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first‑half financials, reporting a 2.7 % year‑on‑year...
RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual...
Dizal Pharma Reports 74.4% Revenue Growth in 2025 Semi-Annual Results
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), a China-based company, reported its 2025 semi-annual results,...
Jazz Pharmaceuticals Secures Global Rights to Saniona’s Epilepsy Drug SAN2355
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Saniona (STO: SANION) announced today that they have entered...
Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six...
Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter
China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License...
Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China
Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that an amendment...
Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion
Shanghai Wankexin Biotechnology Partnership Enterprise (Limited Partnership) (“Wankexin Biotech”), a subsidiary of the Shanghai Biomedicine...
Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based...
Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development
Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...
Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion
German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...
Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...
CR Medical Holdings Partners with Shanghai Haohai Bio in Medical Aesthetics Sector
China Resources Medical Holdings Company Limited has entered into a strategic partnership with Shanghai Haohai...
Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China
China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical...